| COMPANY |
AnaptysBio, Inc. |
| COURT |
United States District Court for the Southern District of California |
| CASE NUMBER |
20-cv-00565 |
| JUDGE |
The Honorable Todd W. Robinson |
| CLASS PERIOD |
October 10, 2017 – November 7, 2019 |
| SECURITY TYPE |
Common Stock |
Case Background:
On March 25, 2020, the initial complaint in this securities class action was filed against AnaptysBio, Inc. (“AnaptysBio” or the “Company”), and certain of AnaptysBio’s directors and officers, asserting violations of Sections 10(b) and 20(a) of the Securities Exchange Act. This is a federal securities class action brought on behalf of all investors who purchased or otherwise acquired AnaptysBio common stock between October 10, 2017 and November 7, 2019, (“Class Period”) both dates inclusive.
The complaint alleges that, throughout the Class Period, Defendants made false and misleading statements regarding the purported efficacy of etokimab, touting data from the Company's Phase 2a trial in peanut allergies as showing a "remarkable efficacy result" and describing the drug as having a "pretty profound efficacy" in its treatment of patients with atopic dermatitis based on AnaptysBio's Phase 2a trial data for that indication. Specifically, the complaint alleges that Defendants provided misleading clinical trial data which failed to disclose key information and used questionable analysis, making the trial results regarding etokimab's efficacy and its prospects appear far better than they were.
Current Status of Case:
Lead Plaintiff filed a consolidated amended complaint (“Complaint”) on September 30, 2020. Defendants filed a Motion to Dismiss the Complaint on November 24, 2020. On September 20, 2021 Defendant’s Motion to Dismiss was granted, however, Lead Plaintiff was given an opportunity to file an amended complaint. On November 24, 2021, Lead Plaintiff filed a Stipulation of Voluntary Dismissal and subsequently the Court dismissed the claims in their entirety with prejudice.
This action has concluded.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.